{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:17:12Z","timestamp":1773055032990,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Korea Ministry of Health &amp; Welfare","award":["HI16C1559"],"award-info":[{"award-number":["HI16C1559"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hutchinson\u2013Gilford progeria syndrome (HGPS) is an extremely rare premature aging disorder characterized by short stature and atherosclerosis-induced death within teenage years. A 13-year-old male diagnosed with HGPS was administered three intravenous infusions of allogeneic cord blood (CB) cells from unrelated donors at four-month intervals to evaluate the safety and its therapeutic efficacy. Adverse events were monitored in addition to height, weight, laboratory blood tests, joint range of motion (ROM), and carotid Doppler. Cytokine and receptor assays were also performed. The patient exhibited an increase in growth rate for both height and weight. One year after therapy initiation, evident amelioration in pulse wave velocity, bilateral maximal intima-media thickness, and dyslipidemic status were observed, which were in abrupt aggravation prior to treatment. Further, an increase in flexibility occurred in some joints of the upper extremities. No serious adverse events were observed throughout the study period and one year beyond. A molecular assay revealed downregulation of proinflammatory and atherosclerosis, representing cytokine expressions following the administration of CB cells. This is the first reported case of an allogeneic CB trial in a patient with HGPS showing therapeutic effects of CB with improvements in anthropometric measures, joint ROM with amelioration of atherosclerosis, and dyslipidemia induced by anti-inflammatory and anti-atherosclerotic responses.<\/jats:p>","DOI":"10.3390\/ijms222212316","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T08:19:20Z","timestamp":1636964360000},"page":"12316","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Cord Blood Cell Therapy for Hutchinson\u2013Gilford Progeria Syndrome\u2014A Case Report"],"prefix":"10.3390","volume":"22","author":[{"given":"Mi Ri","family":"Suh","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea"},{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikhyun","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea"},{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jongwook","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea"},{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pil-Sung","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seung","family":"Choung","sequence":"additional","affiliation":[{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Ryeong","family":"Sim","sequence":"additional","affiliation":[{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Chan","family":"Ha","sequence":"additional","affiliation":[{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2985","authenticated-orcid":false,"given":"MinYoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Korea"},{"name":"Rehabilitation and Regeneration Research Center, CHA University School of Medicine, Seongnam 13488, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/ejhg.2008.270","article-title":"Increased expression of the Hutchinson\u2013Gilford progeria syndrome truncated lamin A transcript during cell aging","volume":"17","author":"Rodriguez","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39741","DOI":"10.1074\/jbc.R600033200","article-title":"Prelamin A farnesylation and progeroid syndromes","volume":"281","author":"Young","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1073\/pnas.0611640104","article-title":"A lamin A protein isoform overexpressed in Hutchinson\u2013Gilford progeria syndrome interferes with mitosis in progeria and normal cells","volume":"104","author":"Cao","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/ajmg.a.31346","article-title":"Hutchinson-Gilford progeria syndrome: Review of the phenotype","volume":"140","author":"Hennekam","year":"2006","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/scitranslmed.3002346","article-title":"Rapamycin Reverses Cellular Phenotypes and Enhances Mutant Protein Clearance in Hutchinson-Gilford Progeria Syndrome Cells","volume":"3","author":"Cao","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bidault, G., Garcia, M., Capeau, J., Morichon, R., Vigouroux, C., and B\u00e9reziat, V. (2020). Progerin expression induces inflammation, oxidative stress and senescence in human coronary endothelial cells. Cells, 9.","DOI":"10.3390\/cells9051201"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1054-8807(98)00023-4","article-title":"Histological and ultrastructural features of atherosclerosis in progeria","volume":"8","author":"Stehbens","year":"1999","journal-title":"Cardiovasc. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.116.022188","article-title":"Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome","volume":"134","author":"Gordon","year":"2016","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/19491034.2018.1460045","article-title":"An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome","volume":"9","author":"Harhouri","year":"2018","journal-title":"Nucleus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2018.3264","article-title":"Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome","volume":"319","author":"Gordon","year":"2018","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/B978-0-444-62702-5.00018-4","article-title":"Chapter 18\u2014Hutchinson\u2013Gilford progeria syndrome","volume":"Volume 132","author":"Islam","year":"2015","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40265-020-01464-z","article-title":"Lonafarnib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16666","DOI":"10.1073\/pnas.1202529109","article-title":"Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson\u2013Gilford progeria syndrome","volume":"109","author":"Gordon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","unstructured":"Chase, L. (2021, July 06). The 10 Most Expensive Drugs in the U.S., Period. Available online: https:\/\/www.goodrx.com\/blog\/most-expensive-drugs-period\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: A double-edged sword","volume":"6","author":"Hansson","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1161\/ATVBAHA.110.209460","article-title":"Cardiovascular pathology in Hutchinson-Gilford progeria: Correlation with the vascular pathology of aging","volume":"30","author":"Olive","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/rme-2021-0024","article-title":"Mechanisms underlying the therapeutic potential of mesenchymal stem cells in atherosclerosis","volume":"16","author":"Kirwin","year":"2021","journal-title":"Regen. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1038\/s41598-020-61441-0","article-title":"Therapeutic mechanism of cord blood mononuclear cells via the IL-8-mediated angiogenic pathway in neonatal hypoxic-ischaemic brain injury","volume":"10","author":"Cho","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fneur.2019.00357","article-title":"Combining Human Umbilical Cord Blood Cells With Erythropoietin Enhances Angiogenesis\/Neurogenesis and Behavioral Recovery After Stroke","volume":"10","author":"Hwang","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Titov, A., Zmievskaya, E., Ganeeva, I., Valiullina, A., Petukhov, A., Rakhmatullina, A., Miftakhova, R., Fainshtein, M., Rizvanov, A., and Bulatov, E. (2021). Adoptive Immunotherapy beyond CAR T-Cells. Cancers, 13.","DOI":"10.3390\/cancers13040743"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-5-8","article-title":"Cord blood in regenerative medicine: Do we need immune suppression?","volume":"5","author":"Riordan","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-02020-y","article-title":"Potentiation of cord blood cell therapy with erythropoietin for children with CP: A 2 \u00d7 2 factorial randomized placebo-controlled trial","volume":"11","author":"Min","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/stem.1304","article-title":"Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double-blind, randomized, placebo-controlled trial","volume":"31","author":"Min","year":"2013","journal-title":"Stem Cells"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1089\/scd.2015.0074","article-title":"Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy","volume":"24","author":"Kang","year":"2015","journal-title":"Stem Cells Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/sctm.18-0008","article-title":"Allogeneic umbilical cord blood infusion for adults with ischemic stroke: Clinical outcomes from a phase I safety study","volume":"7","author":"Laskowitz","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/HYPERTENSIONAHA.110.152686","article-title":"Reference values of pulse wave velocity in healthy children and teenagers","volume":"56","author":"Reusz","year":"2010","journal-title":"Hypertension"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1203\/PDR.0b013e31815b47ff","article-title":"Pulse wave velocity in end-stage renal disease: Influence of age and body dimensions","volume":"63","author":"Kis","year":"2008","journal-title":"Pediatric Res."},{"key":"ref_28","first-page":"327","article-title":"Assessment of intima-media thickness in healthy children aged 1 to 15 years","volume":"106","author":"Baroncini","year":"2016","journal-title":"Arq. Bras. De Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00431-006-0135-y","article-title":"Characteristics of brachial\u2013ankle pulse wave velocity in Japanese children","volume":"165","author":"Niboshi","year":"2006","journal-title":"Eur. J. Pediatrics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report","volume":"128","author":"FOR","year":"2011","journal-title":"Pediatrics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","article-title":"Closing the gaps in pediatric laboratory reference intervals: A CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children","volume":"58","author":"Colantonio","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2257.1997.00204.x","article-title":"Haematological reference ranges for schoolchildren","volume":"19","author":"Taylor","year":"1997","journal-title":"Clin. Lab. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/bja\/aeq258","article-title":"Thromboelastometry (ROTEM\u00ae) in children: Age-related reference ranges and correlations with standard coagulation tests","volume":"105","author":"Oswald","year":"2010","journal-title":"Br. J. Anaesth."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.186.8.1201","article-title":"Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis","volume":"186","author":"Desbaillets","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJMoa0706898","article-title":"Phenotype and course of Hutchinson\u2013Gilford progeria syndrome","volume":"358","author":"Merideth","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4274\/jcrpe.v3i1.02","article-title":"Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatasez-scores in different types of rickets","volume":"3","author":"Turan","year":"2011","journal-title":"J. Clin. Res. Pediatric Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/clinchem\/41.5.672","article-title":"Bone alkaline phosphatase and height velocity in short normal children undergoing growth-promoting treatments: Longitudinal study","volume":"41","author":"Crofton","year":"1995","journal-title":"Clin. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/jhg.2017.90","article-title":"The clinical characteristics of Asian patients with classical-type Hutchinson\u2013Gilford progeria syndrome","volume":"62","author":"Takemoto","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1542\/peds.2007-1357","article-title":"Disease progression in Hutchinson-Gilford progeria syndrome: Impact on growth and development","volume":"120","author":"Gordon","year":"2007","journal-title":"Pediatrics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/jbmr.392","article-title":"Hutchinson-gilford progeria is a skeletal dysplasia","volume":"26","author":"Gordon","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-7-65","article-title":"Development of lower limb range of motion from early childhood to adolescence in cerebral palsy: A population-based study","volume":"7","author":"Nordmark","year":"2009","journal-title":"BMC Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/B978-0-444-62702-5.00018-4","article-title":"Chapter 18-Hutchinson\u2013Gilford progeria syndrome","volume":"132","author":"Ullrich","year":"2015","journal-title":"Neurocutaneous Syndromes. Handb. Clin. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/01.CIR.0000033824.02722.F7","article-title":"Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function?","volume":"106","author":"Cruickshank","year":"2002","journal-title":"Circulation"},{"key":"ref_44","first-page":"21","article-title":"Intima-media thickness: Appropriate evaluation and proper measurement","volume":"13","author":"Simova","year":"2015","journal-title":"Eur. Soc. Cardiol. Ej Cardiol. Pr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jpeds.2004.10.064","article-title":"Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: Clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome","volume":"146","author":"Gordon","year":"2005","journal-title":"J. Pediatrics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11886-011-0220-3","article-title":"The role of triglycerides in atherosclerosis","volume":"13","author":"Talayero","year":"2011","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-immunol-030409-101305","article-title":"An integrated view of humoral innate immunity: Pentraxins as a paradigm","volume":"28","author":"Bottazzi","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.1073\/pnas.92.22.10119","article-title":"Processing and cryopreservation of placental\/umbilical cord blood for unrelated bone marrow reconstitution","volume":"92","author":"Rubinstein","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12316\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:30:19Z","timestamp":1760167819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":48,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222212316"],"URL":"https:\/\/doi.org\/10.3390\/ijms222212316","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}